

## Supplementary Methods

### Survival Analysis

For incident DCM and CHF, disease-free survival was defined as the duration between the start of follow-up time and the date of death, disease onset, or censoring. For all-cause mortality, survival was defined as the duration between the start of follow-up time and the date of death or censoring. The censoring date was defined as March 31, 2017 for disease ascertainment, and January 31, 2018, for mortality ascertainment. At the time of analysis, these were the dates at which 90% of the records were estimated to be complete according to the UK Biobank [https://biobank.ctsu.ox.ac.uk/crystal/exinfo.cgi?src=Data\\_providers\\_and\\_dates](https://biobank.ctsu.ox.ac.uk/crystal/exinfo.cgi?src=Data_providers_and_dates) . Five-year survival estimates were computed with survfit from the survival package.

For incident DCM, CHF, mortality, and the composite of all 3 outcomes, secondary Cox proportional hazards analyses were conducted with adjustment for alcohol consumption, smoking status, hypertension, diabetes, and BMI (all at the time of enrollment).

### Supplementary Tables

Supplementary Table 1: Disease phenotypes

Disease phenotype	Definition
All-cause Heart Failure	Self-reported history of heart failure or cardiomyopathy during verbal interview with trained nurse; <b>or</b> hospitalization for or death due to ICD-10 code for hypertensive heart disease, cardiomyopathy or heart failure (I11.0, I13.0, I13.2, I25.5, I42.0, I42.5, I42.8, I42.9, I50.0, I50.1, I50.9); <b>or</b> hospitalization due to ICD-9 code for heart failure or other primary cardiomyopathies (4254, 4280, 4281, 4289); <b>excluding</b> individuals with history of hypertrophic cardiomyopathy during verbal interview with trained nurse, or hospitalization for or death due to ICD-10 code for hypertrophic cardiomyopathy (I42.1, I42.2)
Dilated Cardiomyopathy	Hospitalization for or death due to ICD-10 code for dilated cardiomyopathy (I42.0); <b>excluding</b> individuals with history of coronary artery disease (as defined below), or history of hypertrophic cardiomyopathy during verbal interview with trained nurse, or hospitalization for or death due to ICD-10 code for hypertrophic cardiomyopathy (I42.1, I42.2)
Coronary Artery Disease	Self-reported history of myocardial infarction (MI), coronary artery bypass grafting, coronary artery angioplasty or triple heart bypass during verbal interview with trained nurse; <b>or</b> hospitalization for or

	death due to ICD-10 code for acute or subsequent myocardial infarction (I21, I22, I23, I24.1, I25.2); <b>or</b> hospitalization due to ICD-9 code for myocardial infarction (410, 411, 412); <b>or</b> hospitalization due to OPCS-4 code for coronary artery bypass grafting (K40, K41, K44, K45, K46), coronary endarterectomy (K47.1), or coronary angioplasty ± stenting (K49, K50.2, K75)
--	--

Supplementary Table 2: Characteristics of participants by ancestry

	European Ancestry		Non-European Ancestry	
	TTNtv carriers	TTNtv Noncarriers	TTNtv carriers	TTNtv Noncarriers
<b>N</b>	153	36,735	13	2,864
<b>Women</b>	91 (60%)	20,444 (56%)	10 (77%)	1,684 (59%)
<b>Age at enrollment (years)</b>	57.8 (45-70.5)	58.2 (45.5-70.9)	56.1 (46.6-65.6)	52 (38.3-65.6)
<b>HDL cholesterol (mmol/L)</b>	1.5 (0.9-2)	1.4 (0.9-2)	1.5 (1.1-1.8)	1.4 (0.9-1.9)
<b>Total cholesterol (mmol/L)</b>	5.8 (4.3-7.2)	5.7 (4.2-7.2)	5.1 (4.5-5.7)	5.4 (4-6.8)
<b>BMI (kg/m<sup>2</sup>)</b>	26.4 (20.1-32.7)	26.6 (20.9-32.3)	29.9 (20.5-39.4)	27 (20.6-33.4)
<b>Height (cm)</b>	167 (154-180)	168 (154-182)	160 (151-169)	165 (152-178)
<b>Weight (kg)</b>	75.9 (55.6-96.2)	76.6 (55.5-97.7)	71 (51.2-90.8)	74.4 (52.5-96.3)
<b>SBP (mmHg)</b>	135 (114-156)	136 (112-160)	132 (115-149)	133 (109-157)
<b>Alcohol intake (standard drinks per week)</b>	5.8 (0-20)	6 (0-18)	0 (0-0)	0 (0-4.5)
<b>Type 2 Diabetes</b>	4 (2.6%)	804 (2.2%)	2 (15.4%)	116 (4.1%)
<b>Hypertension</b>	40 (26.1%)	10423 (28.4%)	3 (23.1%)	874 (30.5%)
<b>Current smoking</b>	11 (7.2%)	3246 (8.8%)	1 (7.7%)	306 (10.7%)
<b>MRI Subset</b>				
<b>N</b>	41	9511	2	352
<b>Women</b>	24 (58.5%)	5021 (52.8%)	1 (50%)	168 (47.7%)
<b>Age at time of MRI (years)</b>	62.5 (54.8-70.1)	62.6 (55.1-70)	61.8 (61-62.6)	58.8 (50.9-66.6)
<b>LVEF (%)</b>	60 (51-68)	65 (59-70)	65 (56-73)	66 (61-71)
<b>LVESV (mL)</b>	59 (35-83)	49 (34-65)	34.9 (29.4-40.5)	44.9 (25.8-63.9)
<b>LVEDV (mL)</b>	143 (111-174)	138 (110-167)	100 (90.6-109.3)	129.1 (98.1-160.2)

## Supplementary Figures

Supplementary Figure 1: Truncating variants in *TTN* yield an increased hazard ratio for the development of incident DCM, CHF, and mortality

